Researchers use our
technologies in their quest
to cure diseases like cancer,
HIV, and Parkinson’s
Chromatin Context-Sensitive Gene-Editing Endonuclease
Many uses of gene-editing proteins are limited by their specificity (“off-target” effects), which can be of particular concern when these proteins are delivered or expressed in vivo.
Our scientists developed a novel high-specificity gene-editing endonuclease that exhibits high-efficiency on-target cutting and enhanced sensitivity to the chromatin context of the target site. The protein comprises an array of DNA-binding repeat sequences connected by flexible linkers. This technology can be used to target cutting activity to genes that are actively expressed, reducing off-target effects, minimizing cellular toxicity, and enabling enhanced safety for therapeutic use.
The Chromatin Context-Sensitive Gene-Editing Endonuclease is protected by seven U.S. patents, as well as patents in Australia, Japan, and Mexico (with additional patents pending in the U.S. and in other countries). Of note, certain granted patents include claims that are not limited by disease indication, cell type, target sequence, or vector.
- Ultra-high efficiency editing of primary cells (up to 100% by IDAA assay1)
- Ultra-high specificity gene editing (e.g., express gene-editing proteins with 36-40-base target sequences)
- Combine with Factor’s mRNA Vectorization of Gene-Editing Proteins technology for virus-free and DNA-free gene editing
- Gene repair using a DNA-repair template
- Donor sequence insertion into a target genomic locus (e.g., TRAC, AAVS1 safe harbor, etc.)
- Gene-editing therapies (ex vivo and in vivo)
- Autologous and allogeneic engineered cell therapies (e.g., CAR-T, CAR-NK, stem cell-derived therapies, etc.)
- Combine with Factor’s mRNA Cell Reprogramming technology to generate models of genetic disease, gene-corrected patient-specific cell therapies, and allogeneic (i.e., immuno-nonreactive or “stealth”) cell therapies, including allogeneic pluripotent stem cell-derived CAR-T and CAR-NK cell therapies for the treatment of cancer, and engineered mesenchymal stem cell (MSC) therapies for regenerative medicine, wound-healing, inflammatory and auto-immune diseases, and tumor-targeting applications
1Kopacz, M., et al. Mol Ther, Vol 28 No 4S1, 2020.
Figure 1. Example Chromatin Context-Sensitive Gene-Editing Endonuclease DNA-binding domain.
Figure 2. High-efficiency gene editing of the AAVS1 genomic safe harbor locus in human iPS cells.